抗癲癇藥物市場：依世代、給藥途徑、通路和地區分類。

Antiepileptic Drugs Market, By Generation, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，抗癲癇藥物市場規模將達到77.4億美元，到2033年將達到98.5億美元。預計從2026年到2033年，該市場將以3.5%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	77.4億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	3.50%	2033年市場規模預測：	98.5億美元

癲癇是一種影響大腦並導致頻繁發作的慢性疾病。癲癇發作是指腦部突然出現的異常放電，會暫時影響腦部功能。癲癇可發生於任何年齡，但通常始於兒童或60歲以後。醫生會進行多項檢查來評估腦部活動。對於癲癇患者，腦電圖（EEG）用於檢查大腦中異常的電活動。腦部掃描也用於檢測癲癇可能引起的腦部問題，例如異常增生（腦腫瘤）、腦損傷和腦部瘢痕。磁振造影（MRI）掃描也用於癲癇患者的腦部檢查。 MRI利用磁場和無線電波產生腦部影像。抗癲癇藥物也用於治療癲癇，這些藥物分為三代。

市場動態

新產品上市數量的增加預計將推動全球抗癲癇藥物市場的發展。例如，2016年1月，邁蘭公司（Mylan NV）推出了400毫克和600毫克劑量的Ferbamate片劑（USP）。 Ferbamate片劑是Fervator片劑的學名藥，用於治療癲癇。此藥建議用於治療成人癲癇患者的局部發作（伴隨或不伴隨繼發性次發性整體發作），以及兒童腸漏症候群相關的局部和整體發作。

然而，抗癲癇藥物的潛在副作用預計將在預測期內阻礙全球抗癲癇藥物市場的成長。例如，根據《家庭醫學雜誌》報導，抗癲癇藥物的副作用之一是，用於治療癲癇患者的苯妥英鈉可能導致一系列畸形，統稱為「胎兒海因症候群（FHS）」。此症候群的特徵是不同程度的遠端指骨畸形或骨化，以及顱顏異常。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及領先企業採取的競爭策略。
本研究根據以下參數對全球抗癲癇藥物市場的主要參與者進行了分析：公司概況、財務績效、產品系列、企業發展地理區域、分銷策略、關鍵發展和整體策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、政府政策、技術升級、市場擴張和行銷策略做出明智的決策。
這份「全球抗癲癇藥物市場報告」旨在為行業內的各類經銷商提供參考，包括相關人員、產品製造商、藥品市場分銷商和供應商、研究和諮詢公司、新參與企業和金融分析師。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- Novartis AG
- GlaxoSmithKline Plc
- Johnson & Johnson Service, Inc.
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Zogenix
- Dr. Reddy's Laboratories Ltd.
- Shanghai Zhimeng Biopharma, Inc.
- Alkem Labs
- SK Biopharmaceuticals
- Eisai Co, Ltd
- IAMA Therapeutics
- Angelini Spa
- Sun Pharmaceutical Industries Ltd.
- UCB SA
- Marinus Pharmaceuticals, Inc.
- Sanofi SA
- Sumitomo Dainippon Pharma Co., Ltd.
- Bausch Health Companies Inc.
- Analysts'Views

第9章

參考
調查方法

簡介目錄

Product Code: CMI1701

Antiepileptic Drugs Market is estimated to be valued at USD 7.74 Bn in 2026 and is expected to reach USD 9.85 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 7.74 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.50%	2033 Value Projection:	USD 9.85 Bn

Epilepsy is a chronic disorder that affects the brain and causes frequent seizures. Seizures are bursts of electrical activity in the brain that temporarily affects its functioning. Epilepsy can start at any age, but usually starts either in childhood or in people over the age of 60. There are several tests conducted to determine the activity in the brain. An electroencephalogram (EEG) is conducted on epilepsy patients to check for unusual electrical activities in the brain. A brain scan is also used to spot problems in the brain that is sometimes caused due to epilepsy such as an unusual growth (brain tumour), damage to the brain, and scarring in the brain. Magnetic resonance imaging (MRI) scan is also used to conduct the brain scan in patients suffering from epilepsy. It uses magnetic fields and radio waves to create an image of the brain. Anti-epileptic drugs are also used in the treatment of epilepsy, which are categorized into three generations.

Market Dynamics

Increasing number of product launches is expected to drive the global anti-epileptic drug market. For instance, in January 2016, Mylan N.V. launched Felbamate tablets USP in 400 mg and 600 mg dosages. Felbamate tablets are the generic version of Felbatol tablets used for the treatment of epilepsy. These are recommended for the treatment of partial seizures, with or without secondary generalizations in adults with epilepsy and in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

However, growth of the global anti-epileptic drug market is expected to be hampered over the forecast period, owing to potential side effects of the anti-epileptic drugs. For instance, according to the Journal of Family Practice, the side effects of anti-epileptic drugs include, the medication Phenytoin, which is used for treating epilepsy patients causes a pattern of defects collectively called the Fetal Hydantoin Syndrome (FHS), which is characterized by variable degrees of hypoplasia and ossification of the distal phalanges and craniofacial abnormalities.

Key features of the study:

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
It profiles key players in the global anti-epileptic drug market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study are Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy's Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A, Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Bausch Health Companies Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics.
The global anti-epileptic drug market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Anti-epileptic Drugs Market, By Generation (Revenue, USD Bn, 2021 - 2033)
First Generation
Second Generation
Third Generation
Global Anti-epileptic Drugs Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
Oral
Intravenous
Global Anti-epileptic Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anti-epileptic Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
- By Generation:
  - First Generation
  - Second Generation
  - Third Generation
- By Route of Administration:
  - Oral
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Europe
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
- By Generation:
  - First Generation
  - Second Generation
  - Third Generation
- By Route of Administration:
  - Oral
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Asia Pacific
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
- By Generation:
  - First Generation
  - Second Generation
  - Third Generation
- By Route of Administration:
  - Oral
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- By Generation:
  - First Generation
  - Second Generation
  - Third Generation
- By Route of Administration:
  - Oral
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
- By Generation:
  - First Generation
  - Second Generation
  - Third Generation
- By Route of Administration:
  - Oral
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
- By Generation:
  - First Generation
  - Second Generation
  - Third Generation
- By Route of Administration:
  - Oral
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
Company Profiles
Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
GlaxoSmithKline Plc.
Johnson & Johnson Service, Inc.
Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
Zogenix
Dr. Reddy's Laboratories Ltd.
Alkem Labs
SK Biopharmaceuticals
Eisai Co., Ltd.
Angelini S.p.a
Sun Pharmaceutical Industries Ltd.
UCB S.A
Sanofi S.A.
Sumitomo Dainippon Pharma Co., Ltd.
Bausch Health Companies Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Generation
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Key Developments
Mergers, Acquisitions and Collaborations
Recent Trends
Recent Launches/Approvals
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
Porter's Analysis

4. Global Antiepileptic Drugs Market, By Generation, 2021-2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
First Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Second Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Third Generation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

5. Global Antiepileptic Drugs Market, By Route of Administration, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends

6. Global Antiepileptic Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

7. Global Antiepileptic Drugs Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth ,By Country, 2021 -2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, and Y-o-Y Growth, By Generation, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and , Y-o-Y Growth, By Country/Region, 2021 -2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GlaxoSmithKline Plc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Johnson & Johnson Service, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Zogenix
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Dr. Reddy's Laboratories Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Shanghai Zhimeng Biopharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Alkem Labs
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- SK Biopharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eisai Co, Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- IAMA Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Angelini S.p.a
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- UCB S.A
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Marinus Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi S.A.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sumitomo Dainippon Pharma Co., Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bausch Health Companies Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Analysts' Views